HKSE:02159's ROE % is ranked better than 69.66% of 623
companies
in the Healthcare Providers & Services industry
Industry Median: 5.86
vs HKSE:02159: 12.38
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Mediwelcome Healthcare Management & Technology ROE % Related Terms
Mediwelcome Healthcare Management & Technology ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mediwelcome Healthcare Management & Technology ROE % vs Healthcare Providers & Services Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Mediwelcome Healthcare Management & Technology (HKSE:02159) has a ROE % of 36.87% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Mediwelcome Healthcare Management & Technology and its competitors. This is 232% above median its historical median of 11.10. According to the industry distribution chart, Mediwelcome Healthcare Management & Technology ranks #189 out of 623 companies in the Healthcare Providers & Services industry, placing it in the top 30.3%.
Is Mediwelcome Healthcare Management & Technology's ROE % too high?
Mediwelcome Healthcare Management & Technology's current ROE % of 36.87% is 232% above median its 10-year median of 11.10. The Healthcare Providers & Services industry median ROE % is 5.86. Mediwelcome Healthcare Management & Technology's value of 36.87% is 529.2% above this industry median. Based on the distribution chart, Mediwelcome Healthcare Management & Technology ranks #189 out of 623 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Mediwelcome Healthcare Management & Technology has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mediwelcome Healthcare Management & Technology's ROE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Mediwelcome Healthcare Management & Technology ranks #189 out of 623 companies for ROE %. This puts Mediwelcome Healthcare Management & Technology in the upper half of its industry. The industry median ROE % is 5.86. Mediwelcome Healthcare Management & Technology's value of 36.87% is 529.2% above this benchmark. While the company's 10-year median is 11.10 vs. the industry median of 5.86, Mediwelcome Healthcare Management & Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.86, based on 623 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mediwelcome Healthcare Management & Technology's current ROE % of 36.87% is 529.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Mediwelcome Healthcare Management & Technology and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mediwelcome Healthcare Management & Technology's current ROE % is 36.87%, which is 232% above median its own 10-year median of 11.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mediwelcome Healthcare Management & Technology stock overvalued right now?
Based on GuruFocus' analysis, Mediwelcome Healthcare Management & Technology (HKSE:02159) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.69, compared to a current price of HK$1.57 — trading 127.5% above its estimated fair value. The current ROE % is 36.87%, which is 232% above median its 10-year median of 11.10 and 529.2% above the Healthcare Providers & Services industry median of 5.86. Mediwelcome Healthcare Management & Technology's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Mediwelcome Healthcare Management & Technology (HKSE:02159), the current ROE % is 36.87% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mediwelcome Healthcare Management & Technology (HKSE:02159) Overvalued in 2026?
Based on GuruFocus' analysis, Mediwelcome Healthcare Management & Technology stock appears to be overvalued.
The current stock price of HK$1.57 is trading 127.5% above its estimated GF Value™ of HK$0.69.
GuruFocus considers Mediwelcome Healthcare Management & Technology to be Significantly Overvalued.
Key valuation signals for HKSE:02159:
ROE %: 36.87% (232% above median its 10-year median of 11.10)
GF Value™: HK$0.69 vs. price of HK$1.57 (127.5% above fair value)
Industry Position: 529.2% above the Healthcare Providers & Services median (#189 of 623)
No single metric tells the full story. See the HKSE:02159 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mediwelcome Healthcare Management & Technology Business Description
Mediwelcome Healthcare Management & Technology Inc is an investment holding company. The Group mainly provides medical conference services, patient education and screening services, and marketing and consulting services, in addition to providing integrated healthcare marketing solutions. Its products and services include Academic Conference Management System, Scientific Research Data Reporting System, the Health/Medical Media Matrix, patient management services, and marketing and consulting services. The Group has only one reportable segment, mainly operating its businesses in the PRC and earning revenue from the PRC.
54GF Score
Get the complete analysis for HKSE:02159
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02159 has been successfully added to your 
